Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer

Head Neck. 2022 Feb;44(2):317-324. doi: 10.1002/hed.26924. Epub 2021 Nov 11.

Abstract

Background: To define the location of the initial contralateral lymph node (LN) metastasis in patients with oropharynx cancer.

Methods: The location of the LN centroids from patients with oropharynx cancer and a single radiographically positive contralateral LN was defined. A clinical target volume (CTV) inclusive of all LN centroids was created, and its impact on dose to organs at risk was assessed.

Results: We identified 55 patients of which 49/55 had a single contralateral LN in level IIA, 4/55 in level III, 1/55 in level IIB, and 1/55 in the retropharynx. Mean radiation dose to the contralateral parotid gland was 15.1 and 21.0 Gy, (p <0.001) using the modeled high-risk elective CTV and a consensus CTV, respectively.

Conclusions: We present a systematic approach for identifying the contralateral nodal regions at highest risk of harboring subclinical disease in patients with oropharynx cancer that warrants prospective clinical study.

Keywords: elective; lymph nodes; oropharynx cancer; radiotherapy; toxicity.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Humans
  • Lymph Nodes / diagnostic imaging
  • Lymph Nodes / pathology
  • Oropharyngeal Neoplasms* / diagnostic imaging
  • Oropharyngeal Neoplasms* / pathology
  • Oropharyngeal Neoplasms* / radiotherapy
  • Parotid Gland
  • Prospective Studies
  • Radiotherapy Dosage
  • Radiotherapy, Conformal*